Midodrine efficacy in orthostatic hypotension. 2014

W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
Department of Neurology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA, singer.wolfgang@mayo.edu.

UI MeSH Term Description Entries
D007024 Hypotension, Orthostatic A significant drop in BLOOD PRESSURE after assuming a standing position. Orthostatic hypotension is a finding, and defined as a 20-mm Hg decrease in systolic pressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the person has risen from supine to standing. Symptoms generally include DIZZINESS, blurred vision, and SYNCOPE. Hypotension, Postural,Orthostatic Hypotension,Postural Hypotension
D008879 Midodrine An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION. Amatine,Gutron,Midodrin,Midodrine Hydrochloride,Midodrine Monohydrochloride,Midon,ProAmatine,ST-1085,Monohydrochloride, Midodrine,ST 1085,ST1085
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014662 Vasoconstrictor Agents Drugs used to cause constriction of the blood vessels. Vasoactive Agonist,Vasoactive Agonists,Vasoconstrictor,Vasoconstrictor Agent,Vasoconstrictor Drug,Vasopressor Agent,Vasopressor Agents,Vasoconstrictor Drugs,Vasoconstrictors,Agent, Vasoconstrictor,Agent, Vasopressor,Agents, Vasoconstrictor,Agents, Vasopressor,Agonist, Vasoactive,Agonists, Vasoactive,Drug, Vasoconstrictor,Drugs, Vasoconstrictor

Related Publications

W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
November 2014, Journal of general internal medicine,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
August 1997, JAMA,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
August 1997, JAMA,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
February 2021, Australian prescriber,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
June 1997, The Medical letter on drugs and therapeutics,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
March 2020, Annals of clinical and translational neurology,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
January 2020, Annals of clinical and translational neurology,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
May 2016, Drug and therapeutics bulletin,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
November 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
W Singer, and M J Joyner, and P Sandroni, and E E Benarroch, and R D Fealey, and J Mandrekar, and P A Low
September 2017, Neurology,
Copied contents to your clipboard!